Eurovive

Eurovive is a French biotechnology company specializing in the development of next-generation Adeno-Associated Virus (AAV) gene therapies for rare genetic disorders. Spun off from the TaRGeT laboratory at Nantes Université and INSERM, the company leverages proprietary AAV vector technology to address significant unmet medical needs. Eurovive's platform focuses on optimizing vector design to improve safety profiles, enhance efficacy, and achieve superior tissue-specific targeting compared to first-generation delivery systems. The company aims to overcome common challenges in gene therapy, such as pre-existing immunity and off-target effects. Currently in the pre-clinical stage, Eurovive is advancing its pipeline toward clinical validation through translational research and strategic partnerships.